European Respiratory Review
Search all ERS
Interstitial Lung Diseases
Respiratory Critical Care
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
ERJ Open Research
European Lung White Book
All ERS guidelines
Global Lung Function Initiative
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases
Colin Holtze, Kevin Flaherty, Michael Kreuter, Fabrizio Luppi, Teng Moua, Carlo Vancheri, Mary B. Scholand
Eur Respir Rev, 27 (150) 180078; 10.1183/16000617.0078-2018
Interstitial lung diseases
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Colin Holtze, Kevin Flaherty, Michael Kreuter, Fabrizio Luppi, Teng Moua, Carlo Vancheri, Mary B. Scholand. Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases. Eur Respir Rev, 27 (150) 180078; 10.1183/16000617.0078-2018
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
No comment yet.
to comment this presentation.
Related content which might interest you:
The impact of anti-IgE treatment on the airway microbiome in asthma.
Quality Improvement in a Sleep Clinic: To increase the capacity and reduce the time to treatment for patients with Obstructive Sleep Apnoea
Endoscopic lung volume reduction with endobronchial valves in very low DLCO patients